VCAN and central nervous system cancer: PI3K/Akt-IN-1 effectively inhibited the pathway, suppressed AP-1 protein, and reduced proliferation driven by VCAN overexpression, indicating that this approach could potentially prevent glioma recurrence on a larger scale.